Trastuzumab-dkst (Ogivri) is biosimilar to Trastuzumab (Herceptin).
Approved 12/01/2017
Trastuzumab-pkrb (Herzuma) is biosimilar to Trastuzumab (Herceptin). Approved 12/14/2018
Trastuzumab-dttb (Ontruzant) is biosimilar to Trastuzumab (Herceptin). Approved 01/18/2019
Trastuzumab-qyyp (Trazimera) is biosimilar to Trastuzumab (Herceptin). Approved 03/11/2019
Trastuzumab-anns (Kanjinti) is biosimilar to Trastuzumab (Herceptin). Approved 06/13/2019
Trastuzumab-strf (Hercessi) is biosimilar to Trastuzumab (Herceptin). Approved 04/25/2024
- TRADE NAME: Herceptin (Genentech)
- INDICATIONS: Metastatic breast cancer; stomach cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, HER2/neu receptor antagonist (HER2 receptor antagonist), Monoclonal antibody, Tyrosine kinase inhibitor
- HALF-LIFE: 2–16 days (dose dependent)
- FDA APPROVAL DATE: 09/25/1998
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Abciximab, Alefacept, Antineoplastics, Azacitidine, Betamethasone, Cabazitaxel, Denileukin, Docetaxel, Doxorubicin, Fingolimod, Gefitinib, Immunosuppressants, Leflunomide, Lenalidomide, Oxaliplatin, Paclitaxel, Pazopanib, Pemetrexed, Pralatrexate, Temsirolimus
CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of trastuzumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/01/2024
